Biologic markers as predictors of cardiovascular disease

American Journal of Medicine

Volumn 104, Issue 6 A, 1998, Pages 18S-27S

  Frishman, William H ^a,b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; CELL ADHESION MOLECULE; CHOLESTEROL; ESTROGEN; FERRITIN; FIBRIC ACID DERIVATIVE; FIBRINOGEN; FIBRINOGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NEOMYCIN; NICOTINIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR; RESIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; VITAMIN D;

ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; DIET RESTRICTION; FIBRINOLYSIS; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; INFECTION; INFLAMMATION; INSULIN RESISTANCE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0031856531     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00184-3     Document Type: Review

References (94)

1. Genest J Jr, Cohn JS. Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol. 1995; 76(suppl):8A-20A.
2. Krauss RM. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J. 1987;113:578-582.
3. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985; 110:1100-1106.
4. Lobo RA. Lipids, clotting factors, and diabetes: endogenous risk factors for cardiovascular disease. Am J Obstet Gynecol. 1988;158:1584-1591.
5. Kannel WB, D'Agostino RB, Wilson PWF, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672-676.
6. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis. 1981;40:1-52.
7. Centers for Disease Control. Effectiveness in disease and injury prevention: public health focus: physical activity and the prevention of coronary heart disease. Morbidity and Mortality Weekly Report. 1993;42:669-672.
8. Elliott WJ. Cardiovascular risk factors: which ones can and should be remedied? Postgrad Med. 1994;96:49-61.
9. Fishbane S, Youn S, Kowalski EJ, Frei GL. Ankle-arm blood pressure index as a marker for atherosclerotic vascular diseases in hemodialysis patients. Am J Kidney Dis. 1995; 25:34-39.
10. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993;88:837-845.
11. Parmley WW. Nonlipoprotein risk factors for coronary heart disease: evaluation and management. Am J Med. 1997; 102:7-14.
12. LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med. 1997;157:961-968.
13. Wilson PWF, Evans JC. Coronary artery disease prediction. Am J Hypertens. 1993;6:309S-313S.
14. O'Keefe JH Jr, Lavie CJ Jr, McCallister BD. Insights into the pathogenesis and prevention of coronary artery disease. Mayo Clin Proc. 1995;70:69-79.
15. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
18. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
19. Tato F, Vega GL, Tall AR, Grundy SM. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vase Biol. 1995; 15:112-120.
20. Nakaya N. Cholesterol ester transfer protein (CETP). Jap J Clin Med. 1994;3164-3169.
21. Franceschini G, Lovati MR, Manazoni C, et al. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis. 1995;114:61-71.
22. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-1449.
23. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
24. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996; 276:875-881.
25. Slyper AH, Zvereva S, Schectman G, et al. Low-density lipoprotein particle size is not a discriminating marker for atherogenic risk in male offspring of parents with early coronary artery disease. Metabolism. 1997;46:954-958.
26. Sherrard B, Simpson H, Cameron J, et al. LDL particle size in subjects with previously unsuspected coronary heart disease: relationship with other cardiovascular risk markers. Atherosclerosis. 1996;126:277-287.
27. Kontopoulos AG, Athyros VG, Papageorgiou AA, et al. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coronary Artery Dis. 1996;7:843-850.
28. Lehtimäki T, Porkka K, Viikari J, et al. Apolipoprotein E phenotypes and serum lipids in newborns and 3-year-old children: the cardiovascular risk in young Finns study. Pediatrics. 1994;94:489-493.
29. Wilson PWF, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA. 1994;272:1666-1671.
30. Luc G, Fievet C, Arveiler D, et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res. 1996;37:508-517.
31. Koren E, Corder C, Mueller G, et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 1996;122:105-115.
32. Alaupovic P, Hodis HN, Knight-Gibson C, et al. Effects of lovastatin on ApoA- and ApoB-containing lipoprotens. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb. 1994;14:1906-1913.
33. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-risk lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997;17:715-722.
34. Yang CY, Gu ZQ, Xie YH. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. Atherosclerosis. 1996;126:105-116.
35. Reguero JJR, Cubero GI, Celada MM, et al. Interrelationships between lipoprotein(a) and other cardiovascular risk factors. Cardiology. 1995;86:432-435.
36. Heinimann K, Stahelin HB, Perrig-Chiello P, et al. Lipoprotein(a) and plasma lipids in 429 elderly and very old subjects: significance as risk factor, effect of nutrition and life style. (Abstr.) Schweiz Med Wochenschr. 1996;126: 1487.
37. Chapman MJ, Huby T, Nigon F, Thillet J. Lipoprotein(a): implication in atherothrombosis. Atherosclerosis. 1994;110: S69-S75.
38. Weber M, McNicoll S, Marcil M, et al. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians. Can J Cardiol. 1997;13:253-260.
39. Duriez P, Dallongeville J, Fruchart JC. Lipoprotein(a) as a marker for coronary heart disease. Br J Clin Prac. 1996; 77A:54-61.
40. Frohlich JJ. Lipoproteins and homocyst(e)ine as risk factors for atherosclerosis: assessment and treatment. Can J Cardiol. 1995;11(suppl 11):18C-23C.
41. Sirtori CR. New targets for lipid lowering and atherosclerosis prevention. Pharmacol Ther. 1995;67:433-447.
42. de Maat MPM, Pietersma A, Kofflard M, et al. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis. 1996; 121:185-191.
43. Wang XL, Wang J, McCredie RM, Wilcken DEL. Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:246-251.
44. Bolibar I, Kienast J, Thompson SG, et al. Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease. Am Heart J. 1993;125:1601-1605.
45. Fogari R, Zoppi A, Marasi G, et al. Associations between plasma fibrinogen levels and cardiovascular risk factors in hypertensive men. J Cardiovasc Risk. 1994;1:341-345.
46. Hawiger J. Mechanisms involved in platelet vessel wall interaction. Thromb Haemost. 1995;74:369-372.
47. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk. 1995;2:197-205.
48. Eber B, Schumacher M. Fibrinogen: its role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost. 1993;19:104-107.
49. de Faire U, Ericsson CG, Grip L, et al. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J. 1996;17(suppl F):37-42.
50. Schoebel FC, Jax TW, Fischer Y, et al. Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris. Heart. 1997;77:13-17.
51. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost. 1995;74:302-308.
52. Smith FB, Lee AJ, Rumley A, et al. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis. 1995;115:35-43.
53. Schleiffer T, Hellstern P, Freitag M, Brass H. Plasminogen activator inhibitor 1 activity and lipoprotein(a) in nephropathic patients with non-insulin-dependent diabetes mellitus versus patients with nondiabetic nephropathy. Haemostasis. 1994;24:49-54.
54. Raskob GE, Durica SS, Morrissey JH, et al. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995;85:3034-3039.
55. Kario K, Matsuo T, Miyata T. Activated factor VII as a new cardiovascular risk factor of atherothrombotic disease. Jap J Clin Pathol. 1995;43:1201-1208.
56. Catto AJ, Grant PJ. Risk factor for cerebrovascular disease and the role of coagulation and fibrinolysis. Blood Coagul Fibrinolysis. 1995;6:497-510.
57. Folsom AR, Qu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:1102-1108.
58. Frishman WH, Weisen S, Lerro KA, et al. Innovative drug targets for treating cardiovascular disease: adhesion molecules, cytokines, neuropeptide Y, and bradykinin. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York: The McGraw-Hill Companies, 1997:881-905.
59. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17 beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest. 1996;98:36-42.
60. Sluiter W, Pietersma A, Lamers JM, Koster JF. Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. J Cardiovasc Pharmacol. 1993;22(suppl 4):S37-S44.
61. Shen Y, Rattan V, Sultana C, Kalra VK. Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. Am J Physiol. 1996;270:H1624-H1633.
62. Hackman A, Yasunori A, Insull W Jr, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996;93:1334-1338.
63. Howard BV. Risk factors for cardiovascular disease in individuals with diabetes. The Strong Heart Study. Acta Diabetol. 1996;33:180-184.
64. Ruiz J, Thillet J, Huby T, et al. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia. 1994;37:585-591.
65. Stern MP. Perspectives in diabetes: diabetes and cardiovascular disease. The common soil hypothesis. Diabetes. 1995;44:369-374.
66. Mediratta S, Fozailoff A, Frishman WH. Insulin resistance in systemic hypertension: pharmacotherapeutic implications. J Clin Pharmacol. 1995;35:943-956.
67. Dhawan J, Bray CL, Warburton R, et al. Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians: genetic or environmental effect? Br Heart J. 1994;72:413-421.
68. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473-486.
69. Tonstad S, Refsum H, Ueland PM. Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia. Circulation. 1997;96:1803-1808.
70. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995;274:1526-1533.
71. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
72. Frishman WH, Fan SC, Boczko J, Husain J. Fish oils, the B vitamins, and folic acid as cardiovascular protective agents. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York: The McGraw-Hill Companies, 1997:511-534.
73. 12 and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: the Bronx Aging Study. Am J Ther. 1997;4:275-281.
74. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart J. 1993;14(suppl K):12-16.
75. Ramirez JA, the Chlamydia pneumoniae/Atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med. 1996;125:979-982.
76. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335: 624-630.
77. Murray LJ, Bamford KB, Reilly DPJ, et al. Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. Br Heart J. 1995; 74:497-501.
78. Gris JC, Granger B, Vecina F, et al. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int. 1994; 46:807-813.
79. Nilsson TK, Hellsten G, Amiral J. Plasma thrombomodulin concentrations in relation to cardiovascular risk factors in a population sample. Blood Coagul Fibrinolysis. 1993;4:455-458.
80. Salonen JT, Nyyssönen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86:803-811.
81. Sempos CT, Looker AC, Gillum RF. Iron and heart disease: the epidemiologic data. Nutr Rev. 1996;54:73-84.
82. Aronow WS, Ahn C. Three-year follow-up shows no association of serum ferritin levels with incidence of new coronary events in 577 persons aged ≥62 years. Am J Cardiol. 1996;78:678-679.
83. Wang XL, Liu S-X, Wilcken DEL. Circulating transforming growth factor β1 and coronary artery disease. Cardiovasc Res. 1997;34:404-410.
84. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755-1760.
85. Hodes RJ, Lakatta EG, McNeil CT. Another modifiable risk factor for cardiovascular disease? Some evidence points to arterial stiffness. J Am Geriatr Soc. 1995;43:581-582.
86. Arnett DK, Evans GW, Riley WA. Arterial stiffness: a new cardiovascular risk factor? Am J Epidemiol. 1994;140:669-682.
87. Kario K, Matsuo T. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. J Cardiovasc Risk. 1994;1:165-171.
88. Daae LNW, Kierulf P, Landaas S, Urdal P. Cardiovascular risk factors: interactive effects of lipids, coagulation and fibrinolysis. Scand J Clin Lab Invest. 1993;215:19-27.
89. Andersen P. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: relationship to the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol. 1992;20(suppl 8): S29-S31.
90. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis. 1993;103:149-157.
91. Munshi MN, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism. 1996;45:133-135.
92. Salomaa V, Riley W, Kark JD, et al. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC study. Circulation. 1995;91:1432-1443.
93. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
94. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360-1369.